Fusion Antibodies and MAB Discovery to collaborate on the development of fully humanized antibodies

04-Apr-2016 - Germany

Fusion Antibodies and MAB Discovery announced their intention to enter into a research and licence agreement in the field of monoclonal antibodies. Within the scope of this collaboration, Fusion Antibodies will apply its proprietary CDRx(TM) Multiplex platform to humanize therapeutic antibodies selected and produced by MAB Discovery. MAB Discovery will provide high-quality humanized antibodies ready for further development to potential partners.

"We are very pleased to be working with Fusion Antibodies, a well-respected antibody engineering firm with strong expertise in humanization," said Dr. Stephan Fischer, Chief Executive Officer of MAB Discovery. "The planned collaboration will enable us to provide our customers added value by offering high-quality humanized antibodies that are ready to be validated and brought into development. We also expect that combining our technologies will reduce the time from target to clinical candidate."

"Through this collaboration we are able to create synergies and provide clients with perfect antibody candidates. They will get access to rapid discovery and development of new antibodies through MAB Discovery's unique immunization and B cell cloning technology. MAB Discovery has developed a rabbit-based platform that produces monoclonal antibodies with unprecedented epitope coverage and potency," said Dr. Paul Kerr, Managing Director at Fusion Antibodies.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous